AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1015 participants.

Also called NCT03192215

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 1,015 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03192215
Other papers using this trial's data
  • Apixaban Versus Aspirin to Reduce Cognitive Decline After Cryptogenic Stroke and Atrial Cardiopathy: ARCADIA-Cognition Study Journal of the American Heart Association, 2025-09-16 DOI, PubMed 40847528, PMC12554400 In the PMC Open Access subset under CC BY-NC-ND.
  • Apixaban to Prevent Covert Infarcts After Cryptogenic Stroke in Patients With Atrial Cardiopathy: A Secondary Analysis of the ARCADIA Randomized Clinical Trial JAMA neurology, 2025-03-01 DOI, PubMed 39869342, PMC11773411 Not in the PMC Open Access subset.
  • Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke: A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial JAMA neurology, 2024-09-01 DOI, PubMed 39133474, PMC11320331 Not in the PMC Open Access subset.
  • Diagnosis of Incident Cancer After Cryptogenic Stroke: An Exploratory Analysis of the ARCADIA Randomized Trial Neurology, 2024-11-26 DOI, PubMed 39481070, PMC11527484 Not in the PMC Open Access subset.
  • History of Cancer and Atrial Cardiopathy: A Secondary Analysis of the ARCADIA Clinical Trial Journal of the American Heart Association, 2025-05-06 DOI, PubMed 40265582, PMC12184225 In the PMC Open Access subset under CC BY-NC-ND.
  • Hypertension With High-Risk Features in Cryptogenic Stroke: An Exploratory Analysis of the ARCADIA Randomized Clinical Trial JAMA neurology, 2026-06-01 DOI, PubMed 42008258, PMC13097029 In the PMC Open Access subset under CC BY.
  • Premature Atrial Contractions as a Marker of Atrial Cardiopathy: A Revised Analysis of the ARCADIA Randomized Trial Journal of cardiovascular electrophysiology, 2025-07 DOI, PubMed 40294164, PMC13120839 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03192215. Randomized; quadruple masking; primary purpose prevention. Start 2018-01-19 (actual); primary completion 2023-03-31 (actual). Results posted on 2025-04-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
Acronym
ARCADIA
Condition
Stroke
Intervention (Drug)
Apixaban
Intervention (Drug)
Aspirin
Lead sponsor
Columbia University (class: other)
Collaborator
National Institute of Neurological Disorders and Stroke (NINDS) (class: US National Institutes of Health)
Collaborator
University of Cincinnati (class: other)
Collaborator
Medical University of South Carolina (class: other)
Collaborator
Bristol-Myers Squibb (class: industry)
Collaborator
Pfizer (class: industry)
Collaborator
Roche Pharma AG (class: industry)
Collaborator
Weill Medical College of Cornell University (class: other)
Collaborator
University of Washington (class: other)

Record details

Record id
cardio:ct-nct03192215
Content hash
1900de817370977648e43fa5569794857e39043492d52789d1ed3153d91215dc